Elevance Health (NYSE:ELV) Releases Earnings Results, Beats Estimates By $0.04 EPS

Elevance Health (NYSE:ELV) released its earnings results on Thursday. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.80 by $0.04, Zacks reports. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. Elevance Health updated its FY 2025 guidance to 34.150-34.850 EPS.

Elevance Health Price Performance

NYSE:ELV opened at $390.21 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. The stock has a market cap of $90.50 billion, a P/E ratio of 14.23, a PEG ratio of 1.10 and a beta of 0.84. The company has a fifty day moving average price of $386.32 and a 200 day moving average price of $463.64. Elevance Health has a one year low of $362.21 and a one year high of $567.26.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be paid a $1.71 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 annualized dividend and a dividend yield of 1.75%. Elevance Health’s dividend payout ratio (DPR) is presently 23.77%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ELV. StockNews.com raised Elevance Health from a “hold” rating to a “buy” rating in a research note on Friday, January 17th. UBS Group cut their price target on shares of Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a report on Friday, October 18th. Wells Fargo & Company dropped their price target on Elevance Health from $593.00 to $495.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. TD Cowen decreased their price objective on Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a research report on Monday, October 21st. Finally, Royal Bank of Canada reduced their price target on shares of Elevance Health from $585.00 to $478.00 and set an “outperform” rating for the company in a research report on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $524.87.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.